ClinicalTrials.gg
RecruitingNCT07665762Updated Sep 8, 2026

Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain

A Phase 3 interventional study of 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine and 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone in Pain, Postoperative, Liposomal Bupivacaine and Dexamethasone, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by The University of Hong Kong · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pain, Postoperative by The University of Hong Kong — 3 open to participants now, 3 under way, 2 of them phase 3. Pain, Postoperative · The University of Hong Kong.

Planned enrollment
6th of 11
90 · median 90
Started
2026
the only one that year
Phase 3
4 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Pain, Postoperative by The University of Hong Kong, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 3, and was the 14th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 14 studies in Pain, Postoperative by The University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pain, Postoperative by The University of Hong Kong, or all of them as a file.
02

Study summary

The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.

A randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and/or higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.

03

Conditions studied

  • Pain, Postoperative
  • Liposomal Bupivacaine
  • Dexamethasone
  • Supraclavicular Brachial Plexus Block
  • High Risk Factors
  • Distal Radial Fracture

Keywords

  • supraclavicular brachial plexus block
  • liposomal bupivacaine
  • dexamethasone
  • distal radial fracture
  • pain
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) status I-III
  • Age 18-90 years old
  • Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)
  • obtained
  • Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:

    • Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6/10 with arm movements at day before surgery.
    • Preoperative use of opioid: use of strong opioids such as morphine, oxycodone
    • Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above
    • Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above
    • Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant

Exclusion criteria

Exclusion Criteria:

  • Revision surgery
  • Previous fractures or surgery in the affected distal radius
  • Surgery involving more than the affected arm
  • Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100
  • Respiratory compromise (requires long term oxygen)
  • History of seizures
  • Pre-existing neurological disorder/deficit
  • Alcohol or substance abuse
  • Impaired mental state
  • Local infection
  • Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids
  • Impaired renal function (defined as effective \< 30ml/min/1.73m2
  • Impaired liver function (defined as plasma over 34μmol/L; [INR] ≥1.7, [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L)
  • Coagulopathy ( count \<100,000/ml and/or INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB
  • Pregnancy
  • Patient refusal for regional nerve blocks
  • Patient refusal to join the clinical trial
  • Patient unable/unwilling to attend post-op rehabilitation programme
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    SBPB using 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine (LP-BPB)

    Supraclavicular brachial plexus block with 10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine

    Drug: 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine

  • Experimental
    SBPB using 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone (D-BPB)

    Supraclavicular brachial plexus block using 19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone

    Drug: 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone

Interventions

  • Drug10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine

    10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine (133mg)

  • Drug19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone

    19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone

06

What researchers measure

Primary outcomes

  1. Weighted area under curve (AUC) pain score with movement

    The weighted area under curve (AUC) numerical rating scale (NRS) pain score with movement (active wrist flexion and extension) from 0-48 hours after distal radial fracture surgery.

    Time frame: The first 48 hours after surgery

Secondary outcomes

  1. NRS pain scores

    NRS pain scores both at rest and with movement will be assessed from after surgery to POD 7. (NRS scale 0-10, where 0 is no pain, and 10 is the worst possible pain)

    Time frame: Postoperative day 0-7

  2. Overall Benefit of Analgesic Score (OBAS)

    Overall Benefit of Analgesic Score (OBAS) will be assessed once a day until POD 7 (range, 0 \[best\] to 28 \[worst\]).

    Time frame: Postoperative day 0-7

  3. Acute postoperative opioid consumption

    The daily consumption of oxycodone in the ward and after discharge will be recorded. The dose of rescue intravenous morphine consumption in the PACU will also be recorded.

    Time frame: Postoperative day0-7

  4. Sleep disturbance

    Sleep disturbance due to pain will be evaluated once a day till POD 7 (0-10, where 0 represents no disturbance and 10 represents the most disturbance possible).

    Time frame: Postoperative day0-7

  5. Quality of recovery (QoR)

    This will be accessed using the Quality of recovery (QoR) questionnaire. (range from 0 to 18, where 0 represent the worst quality of recovery and 18 represent the best quality of recovery)

    Time frame: Postoperative day0-7

  6. Adverse effects related to supraclavicular BPB

    The potential side effects related to the supraclavicular BPB will be recorded.

    Time frame: postoperative day0-2

  7. Opioid related side effects

    Opioid related side effects will be recorded.

    Time frame: postoperative day0-7

  8. Analgesic block duration.

    Time to return of pain, time to sensory resolution, time to motor resolution will be recorded on POD 1.

    Time frame: On postoperative day1

  9. Sensory and motor assessment of the affected upper limb

    Sensation to pin prick will be tested over the following areas: C5 (lateral shoulder), C6 (thumb), C7 (3rd finger), and C8 (4th finger) dermatomes. Motor assessment will be done by recording grip strength and bicep contraction. Sensation will be rated as 0-10 , where 0 represent no sensation and 10 represent normal sensation. Motor function will be rated as 0 (paralysis), 1 (paresis), 2 (normal power).

    Time frame: Postoperative day0-1

  10. Health related quality of life

    Health related quality of life will be assessed using the SF-12v2. Baseline scores will be obtained before surgery. The SF-12v2 will produce two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Both summary scores range from 0 to 100, where higher scores always indicate better physical and mental health.

    Time frame: Baseline and at 3, 6 and 12 weeks after surgery

  11. Upper limb functional scores.

    The validated Chinese versions of the Disabilities of the Arm, Shoulder, and Hand (QuickDASH) will be used to assess upper limb functional scores. Baseline scores will be obtained before surgery. (Range from 0 to 100, a lower score indicates a better outcome)

    Time frame: Baseline and at 3, 6 and 12 weeks after surgery

  12. Hand grip power of normal and injured side

    Hand grip power of normal and injured side will be assessed (both hands).

    Time frame: At 3, 6 and 12 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 24 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 24, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Mar 1, 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07665762
Responsible party
Wong Sau Ching Stanley (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Jun 24, 2026
Start date
Aug 4, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Stanley S.C. Wong
Contact
wongstan@hku.hk
(852) 2255 3303

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion